Elmind Capital, LP
13F holdings for Q2 2026 · NEW YORK, NY · filed August 14, 2026
Elmind Capital, LP reported $398M in 13F securities across 35 holdings for Q2 2026, in a Form 13F filed August 14, 2026. The largest positions were COGT (11.4%), SNDX (10.2%), CLDX (9.3%). Reported value rose 13.0% from the quarter before. It opened 6 new positions, added to 9, trimmed 6 and sold out of 5.
- 13F value Q2 2026
- $398M
- Holdings
- 35
- Change vs prior quarter
- +13.0%
- Rank by 13F value
- #4,469
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Top holdings
| Stock | Value | Weight | Shares | Change in shares | Move |
|---|---|---|---|---|---|
| COGT Cogent Biosciences Inc. | $45.3M | 11.4% | 1,170,740 | 0% | Unchanged |
| SNDX Syndax Pharmaceuticals Inc. | $40.6M | 10.2% | 1,855,000 | 0% | Unchanged |
| CLDX Celldex Therapeutics Inc. | $36.8M | 9.3% | 990,000 | +14.5% | Added |
| RLAY Relay Therapeutics Inc. | $27.4M | 6.9% | 1,465,279 | +172.9% | Added |
| PCVX Vaxcyte Inc. | $26.3M | 6.6% | 452,340 | +42.9% | Added |
| VERA Vera Therapeutics Inc. | $18.7M | 4.7% | 436,518 | -9.5% | Trimmed |
| Pharvaris NV | $18.2M | 4.6% | 525,750 | +10.5% | Added |
| VRDN Viridian Therapeutics Inc. | $18.1M | 4.5% | 984,931 | +84.1% | Added |
| CTMX CytomX Therapeutics Inc. | $17.1M | 4.3% | 4,550,000 | 0% | Unchanged |
| TVTX Travere Therapeutics Inc. | $16.6M | 4.2% | 292,600 | +64.8% | Added |
| LEGN Legend Biotech Corporation | $16.5M | 4.1% | 570,569 | New | New |
| BEAM Beam Therapeutics Inc. | $16.3M | 4.1% | 476,338 | 0% | Unchanged |
| CGEM Cullinan Therapeutics Inc. | $12.6M | 3.2% | 690,000 | +30.2% | Added |
| NRIX Nurix Therapeutics Inc. | $11.2M | 2.8% | 460,000 | 0% | Unchanged |
| KRYS Krystal Biotech Inc. | $8.2M | 2.1% | 22,000 | 0% | Unchanged |
| UTHR United Therapeutics Corporation | $8.1M | 2.0% | 15,000 | 0% | Unchanged |
| SMMT Summit Therapeutics Inc. | $7.2M | 1.8% | 493,820 | New | New |
| INSM Insmed Incorporated | $6.9M | 1.7% | 65,000 | New | New |
| BCRX BioCryst Pharmaceuticals Inc. | $5.2M | 1.3% | 520,000 | -48.0% | Trimmed |
| MBX MBX Biosciences Inc. | $5.0M | 1.3% | 91,000 | -56.9% | Trimmed |
| PTGX Protagonist Therapeutics Inc. | $4.7M | 1.2% | 38,000 | 0% | Unchanged |
| Urogen Pharma LTD | $4.4M | 1.1% | 120,000 | -45.5% | Trimmed |
| DBVT DBV Technologies S.A. | $4.3M | 1.1% | 265,000 | 0% | Unchanged |
| ALMS Alumis Inc. | $3.7M | 0.9% | 130,000 | 0% | Unchanged |
| Supernus Pharmaceuticals | $3.3M | 0.8% | 70,000 | +250.0% | Added |
Share positions only, at the value reported for the end of Q2 2026. Weight is the share of $398M in share positions; options and bonds count in the 13F value but not here.
Biggest buys in Q2 2026
- RLAY Relay Therapeutics Inc. Added+$17.4M
- LEGN Legend Biotech Corporation New+$16.5M
- VRDN Viridian Therapeutics Inc. Added+$8.3M
- PCVX Vaxcyte Inc. Added+$7.9M
- SMMT Summit Therapeutics Inc. New+$7.2M
- INSM Insmed Incorporated New+$6.9M
- TVTX Travere Therapeutics Inc. Added+$6.5M
- CLDX Celldex Therapeutics Inc. Added+$4.7M
- CGEM Cullinan Therapeutics Inc. Added+$2.9M
- Supernus Pharmaceuticals Added+$2.3M
Biggest sells in Q2 2026
- Kalvista Pharmaceuticals Inc Sold out-$20.6M
- CGON CG Oncology Inc. Sold out-$19.7M
- TYRA Tyra Biosciences Inc. Trimmed-$10.5M
- MBX MBX Biosciences Inc. Trimmed-$6.6M
- BCRX BioCryst Pharmaceuticals Inc. Trimmed-$4.8M
- Urogen Pharma LTD Trimmed-$3.7M
- Apellis Pharmaceuticals Inc Sold out-$2.0M
- VERA Vera Therapeutics Inc. Trimmed-$2.0M
- DSGN Design Therapeutics Inc. Trimmed-$1.4M
- enGene Holdings Inc. Sold out-$1.4M
The change in shares since Q1 2026, adjusted for stock splits and priced at the Q2 2026 value per share. 6 new, 9 added, 6 trimmed, 5 sold out.
Sector mix
- Health Care93.2%
- Not listed with us6.8%
13F value by quarter
More holdings
| Stock | Value | Weight | Shares | Change in shares | Move |
|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical Inc. | $2.7M | 0.7% | 47,000 | 0% | Unchanged |
| IMCR Immunocore Holdings plc | $2.6M | 0.6% | 81,143 | +39.3% | Added |
| AMLX Amylyx Pharmaceuticals Inc. | $2.0M | 0.5% | 112,000 | 0% | Unchanged |
| ALEC Alector Inc. | $1.8M | 0.5% | 900,000 | 0% | Unchanged |
| SEPN Septerna Inc. | $1.7M | 0.4% | 49,444 | New | New |
| DSGN Design Therapeutics Inc. | $1.6M | 0.4% | 107,900 | -48.1% | Trimmed |
| STRO Sutro Biopharma Inc. | $1.1M | 0.3% | 32,037 | New | New |
| Wave Life Sciences LTD SHS | $1.0M | 0.3% | 177,846 | 0% | Unchanged |
| TYRA Tyra Biosciences Inc. | $639K | 0.2% | 20,000 | -94.3% | Trimmed |
| ENGN enGene Therapeutics Inc. | $363K | 0.1% | 210,000 | New | New |
Questions about Elmind Capital, LP
- What does Elmind Capital, LP own?
- In its Form 13F for Q2 2026, Elmind Capital, LP reported 35 holdings worth $398M. The five largest were COGT, SNDX, CLDX, RLAY, PCVX.
- What did Elmind Capital, LP buy and sell in Q2 2026?
- Elmind Capital, LP opened 6 new positions, added to 9, trimmed 6 and sold out of 5 compared with the quarter before.
- When did Elmind Capital, LP file its latest 13F?
- Form 13F is due 45 days after each quarter ends. The Q2 2026 report was due August 14, 2026 and was filed August 14, 2026.
From Form 13F filed by Elmind Capital, LP (SEC CIK 0002052213) for the quarter ended June 30, 2026, via the SEC's Form 13F data sets. Amendments that restate a report replace it; amendments that add holdings are included. View on SEC EDGAR · All funds · Get this as JSON